Much progress has been made in the last decade in identifying genes responsible for antifungal resistance in Candida albicans. Attention has focused on five major C. albicans genes: ABC transporter genes CDR1 and CDR2, major facilitator efflux gene MDR1, and ergosterol biosynthesis genes ERG11 and ERG3. Resistance involves mutations in 14C-lanosterol demethylase, targeted by fluconazole (FLZ) and encoded by ERG11, and mutations that up-regulate efflux genes that probably efflux the antifungals. Mutations that affect ERG3 mutations have been understudied as mechanism resistance among clinical isolates. In vitro resistance in clinical isolates typically involves step-wise mutations affecting more than one of these genes, and often unidentified genes. Different approaches are needed to identify these other genes. Very little is understood about reversible adaptive resistance of C. albicans despite its potential clinical significance; most clinical failures to control infections other than oropharyngeal candidiasis (OPC) occur with in vitro susceptible strains. Tolerance of C. albicans to azoles has been attributed to the calcineurin stress-response pathway, offering new potential targets for next generation antifungals. Recent studies have identified genes that regulate CDR1 or ERG genes. The focus of this review is C. albicans, although information on Saccharomyces cerevisiae or Candida glabrata is provided in areas in where Candida research is underdeveloped. With the completion of the C. albicans genomic sequence, and new methods for high throughput gene overexpression and disruption, rapid progress towards understanding the regulation of resistance, novel resistance mechanisms, and adaptive resistance is expected in the near future.
CaErg8p. CaERG5 and CaERG6 have no homologs in man, due to the fact that they catalyze reactions found in ergosterol, not in cholesterol.
ERG11
Azoles are the most widely used antifungals. There are a variety of azoles which all act by binding and inhibiting Erg11p, a cytochrome P450 enzyme lanosterol 14a-demethylase (Fig. 1 ). This inhibition does not block the pathway at lanosterol, athough lanosterol concentrations do increase. Instead, lanosterol with its 14-methyl group intact, is acted on by downstream enzymes to generate 14-methylated intermediates. The model is that one of these intermediates, 14-methylergosta-8,24(28)-dien-3,6-diol, is toxic and is responsible for growth inhibition. The main evidence for this is that mutation or deletion of the gene encoding ScErg3p, which forms this toxic sterol from14-methyl fecosterol, confers resistance to azoles [4, 5] . In this model, reviewed in detail by its authors [6] , it is not the lack of ergosterol that is inhibitory, but the accumulation of the toxic intermediate. They propose that the hydroxyl group on the 6th carbon disrupts hydrophobic interactions of the intermediate with plasma membrane phospholipids permeablizing the membrane. It should be mentioned that the toxic diol model is not universally accepted for C. albicans, primarily because early observations showed that viable ERG11 mutants accumulated significant amounts of the diol [7, 8] . However, this may be a quantitative difference, since the ERG11 mutants show reduced growth. Further detractions include that the identity of the diol in these Fig. 1 Ergosterol biosynthesis pathway and sites of inhibition. The pathway begins with acetyl-CoA on the left, proceeds to lanosterol, and continues on the upper right. Fenpropimorph and the azoles block their indicated enzymes, but downstream enzymes act on the substrates in side reactions to generate toxic sterols that inhibit growth. Statins (Lovastatin shown) and terbinafine inhibit by preventing accumulation of lanosterol, the minimum required sterol. Azoles also inhibit ERG5, and morpholines like Fenpropimorph also inhibit ERG2; zaragozic acid inhibits ERG9 (not shown). ERG25/26/27 indicates the sequential and repeated action of ERG25 (C4-sterol methoxidase), ERG26 (C4-sterol reductase), and ERG27 (C3-sterol ketoreductase) to demethylate C4.
papers is inconsistent with earlier analysis [9] , and that the ERG11 mutant is not characterized; in other work, CaERG11 mutants have had other defects, for example in respiration [10] . Since CaERG3 mutations behave like ScERG3 mutations, discussed below, the toxic sterol model probably applies to C. albicans, although it requires more for complete inhibition than in S. cerevisiae.
At least 12 point mutations among more than 80 polymorphisms in ERG11 confer or are associated with azole resistance (Table 1) . Compelling evidence that the mutation caused resistance in four of these was determined by expressing the wild type C. albicans ERG11 gene in S. cerevisiae, after using site-directed mutagenesis to alter a single base to the mutant sequence, followed by measurement of demethylase activity in vitro or determining resistance of the S. cerevisiae transformant. Nearly as compelling were the 4 additional mutant genes which were cloned into a high copy plasmid and expressed in S. cerevisiae to determine resistance of the transformants relative to control clones [11] . Strong evidence for another four mutants was provided by showing reduced susceptibilities of demethylase activity from clinical resistant Correlative, located in substrate access channel in model [12, 290] Abbreviations: SDD0/susceptible, dose-dependent (resistant in vitro to 8 Á/32 mg/ml FLZ); R: resistant in vitro to 64'/mg/ml FLZ). Methods: SDM0/ Heterologous expression in Saccharomyces cerevisiae of wild type Candida albicans gene after site-directed mutagenesis; SDM-EA0/ In vitro enzyme assays extracts from S. cerevisiae transformed with C. albicans gene which was altered by SDM; /Ca(Sc) 0/Overexpression in S. cerevisiae of cloned genes from resistant isolates of C. albicans ; EA0/ In vitro assays of enzymatic activity of extracts of resistant clinical isolates. Several known and new mutations were reported by (291) , but their link to resistance is uncertain since they only appeared in resistant isolates that had other known resistance mutations and/or upregulation of CDR2. New mutations include: A107T, G448V, V452A, V509M, Y257H, and G307S.
strains. Associative evidence was found for an additional mutation's link to resistance, meaning that it was repeatedly found only in resistant or quasi-resistant (SDD, susceptible, dose-dependent, 0/MIC between 8 and 32 mg/ml) isolates, never in susceptible isolates. Some mutations alter heme binding and reduce demethylase activity, while others alter azole binding without affecting heme binding or demethylase. Recent reviews discuss how these mutations fit into a tentative structural model of the enzyme [6, 12] . Although this integral membrane protein has not been crystallized, homology models based on the crystal structure of CYP51 of Mycobacterium tuberculosis have been constructed [13 Á/17] . Despite differences among these papers, it is clear that azoles bind near the heme group in the enzyme, and mutations that interfere with this interaction confer resistance to azoles. These mutations preferentially affect the short-chained azoles, FLZ and voriconazole, because of additional stabilizing interactions of the long chains of posaconazole and itraconazole with residues along the inner channel 2. Conversely, mutations along channel 2 may confer resistance only to the latter azoles by precluding their binding. Table 1 does not include mutations which have been seen in susceptible isolates, listed in [12] and [11] , since these are less likely to be functionally related to resistance. Despite this, some of these may play a role in resistance. Some polymorphisms, when combined with resistance mutations, further increase the level of resistance [18] . Conversely, mutant S405K alone confers moderate resistance, but is susceptible in combination with some other polymorphisms [12] . These observations suggest that more independent isolates need to be screened for polymorphisms and mutations, and more of these need to be functionally tested.
Does an increased level of Erg11p confer azole resistance? Overexpression of ScERG11 [19] or CgErg11p [20, 21] results in azole resistance. Overexpression of ERG11 is seen in some clinical resistant C. albicans isolates; however, the level of expression is poorly correlated with resistance (discussed later in this review). Our recent development of a reliable multicopy shuttle plasmid for C. albicans has allowed us to address this issue without resorting to heterologous expression. The selective marker in this plasmid is the wild type gene encoding IMP dehydrogenase; only when overexpressed can this gene confer resistance to the IMP analog mycophenolic acid (MPA), forcing amplification of the plasmid to about 40 copies per cell. Wild type genes cloned into the plasmid, behind vectorderived or native promoters, overexpress their product [22] . Overexpression of a fusion product consisting of mostly CaErg11p in C. albicans confers moderate FLZ resistance [22] , and overexpression of the native protein driven by its own promoter confers significant resistance to azoles (unpublished observations). This is expected, since overproduction of the target should allow continued demethylation by enzyme that is not bound by azole. In these transformants, normal to near-normal levels of ergosterol accumulate even in 64 mg/ml FLZ.
The effect of disrupting CaERG11 is not clear. Recently, disruption of both alleles of ERG11 in C. albicans was reported. The disruptant is aerobically viable, and is resistant to high concentrations of FLZ [23] . In contrast, in S. cerevisiae, this deletion, or inactivating point mutations, are lethal unless supplemented with ergosterol and fatty acid under anaerobic conditions, or unless there is a second mutation in ERG3 [4, 5, 7, 24, 25] . The C. albicans result poses a problem for the model for azole mechanism of action, and/or calls into question the genotype of the ERG11 disruptant strain [23] . Deletion of the gene should introduce the same growth-inhibited phenotype as wild type cells inhibited by FLZ, because it should generate an inhibitory concentration of 14-methylergosta-8,24(28)-dien-3,6-diol. That is, the disruptant should be viable but capable of very slow growth at best even in the absence of azole.
One interpretation of the effects of disrupting CaERG11 [23] assumes that the toxic sterol model is basically correct but that the disruptant is complex. It proposes that the viability/growth of the disruptant results either from a regulatory change or from a secondary mutation that reduces this toxic intermediate. This mutation could be anywhere, but a likely target for either is ERG3. This interpretation is favored by the means by which Sanglard's group isolated the disruption in the second ERG11 allele. This derived from the single allele disruptant by selection on Amphotericin B, which selects for strains devoid of ergosterol, rather than by a second round of URA3 blasting, which was attempted but not successful. While it is clear that the second ERG11 allele had been deleted, other mutations may have been selected for, and again the prime suspect is ERG3. Consistently, 14-methylfecosterol is detected in the disruptant, but possibly not the toxic sterol. The authors are keenly aware of this possibility and do mention that they sequenced the ERG3 genes in the disruptants and found no changes. However, it is not clear whether they looked at its expression or function. Alternative interpretations of the CaERG11 disruption are possible but complex.
In a separate study, ERG11 was underexpressed by disrupting one allele and placing the second under control of the tetracycline repressor. Under these conditions, growth was reduced by 90% [3] . While the authors are not clear whether complete inactivation of expression was cidal, these observations suggest that expression is essential for growth. Until these issues are resolved, it is premature to conclude that ERG11 is not essential for growth in wild type C. albicans, or that its deletion confers resistance to azoles.
ERG3 encodes the D5,6 desaturase acting late in the ergosterol biosynthesis pathway (Fig. 1) . Erg3p is responsible for converting tolerated 14-methyl intermediates, which accumulate because of azole inhibition of 14C-lanosterol demethylase, into the toxic sterol 14-methylergosta-8,24(28)-dien-3,6-diol [4, 5] . Therefore, ERG3 inactivation should and does confer azole resistance. Wild type strains exposed to azoles typically accumulate the toxic sterol, whereas ERG3 mutants accumulate mostly ergosta-7, 22-dienol in the absence of azole, instead of ergosterol, and mostly 14a-methylfecosterol after azole exposure, both in S. cerevisiae and C. albicans [6,26Á/28] . Deletions of both alleles of CaERG3 conferred high level azole resistance [23] , suggesting that diol formation by Erg3p is inhibitory in C. albicans as in S. cerevisiae. However, there are differences among yeast species. For example, ERG3 deletion mutants are azole resistant in S. cerevisiae [5] and C. albicans [23] , but not in C. glabrata [25] . Most spontaneous azole-resistant (recessive) mutations in S. cerevisiae occur in the ERG3 gene, which would not be expected in the diploid C. albicans. It is reasonable to expect that mutations that repress transcription of ERG3 could confer resistance in clinical isolates, but these have not been reported or rigorously sought. Sequencing and expression analysis of this gene in clinical isolates therefore needs more attention.
ERG1 encodes squalene epoxidase, which when inhibited by terbinafine results in ergosterol depletion and accumulation of squalene (Fig. 1) . Terbinafine is fungistatic for most Candida species, but fungicidal for filamentous fungi [29 Á/31] . Terbinafine becomes fungicidal for C. albicans in combination with calcineurin inhibitors, an effect also seen with azoles [32, 33] . Strains that are resistant to azoles are normally not cross-resistant to terbinafine [34] , unless resistance is based on overexpression of CDR1.
Analysis of terbinafine-resistant genes in C. albicans isolates are not reported, but studies in S. cerevisiae are instructive. Single point mutations in ERG1 in S. cerevisiae result in terbinafine resistance. Mutants maintain ergosterol in their membranes despite squalene accumulation, suggesting that normal cells are inhibited by the depletion of ergosterol rather than by accumulation of squalene [35, 36] . Unpublished information on the S. cerevisiae database (http://db.yeastgenome.org/cgi-bin/locus.pl?locus 0/erg1) indicates that deletion of ERG1 is lethal unless maintained under anaerobic conditions to allow uptake of exogenous ergosterol. More analysis of CaERG1 is warranted to determine whether C. albicans follows the example of S. cerevisiae.
Can overexpression of ERG1 confer terbinafine resistance? Expression of ERG1 and other ERG genes is increased about 5-fold upon exposure to terbinafine in susceptible strains of C. albicans or S. cerevisiae [37, 38] . Screening of our C. albicans overexpression library resulted in the isolation of an ERG1-overexpressant that was highly resistant to terbinafine, without cross-resistance to azoles (unpublished data). This is consistent with results in Aspergillus fumigatus, in which a plasmid overexpressing ERG1 conferred resistance to terbinafine [39] .
ERG6 encodes C-24 sterol methyltransferase, catalyzing a reaction not shared in cholesterol biosynthesis (Fig. 1) . Hence it is an attractive target for antifungals. Its disruption in S. cerevisiae confers pleiotrophic defects that include slow growth, poor mating, poor uptake of tryptophan, increased permeability, and increased cation and antifungal susceptibilities, suggesting increased membrane permeability [40 Á/43] . Its disruption in C. albicans conferred hypersusceptibility to terbinafine, cycloheximide, fenpropiomorph, and Tridemorph, but not to azoles, and resistance to AMB [44] . The authors surmise that these hypersusceptiblities were due to increased permeability. However, since no direct assays for this were reported, and since deletion of ScERG6 reduced activity of efflux pump Pdr5p [45] , these conclusions are premature. Antifungal inhibitors that target ERG6 should be potent synergens with existing antifungals, if it is shown that antifungal susceptibilities remain high in an ERG6 disruptant that is overexpressing CDR1 or MDR1, to determine whether the increased efflux negates benefits of ERG6 disruption. Overexpression of ERG6 in transformants from our C. albicans library are resistant to azoles (unpublished observation).
ERG24 encodes C14-sterol reductase, which finalizes the C-14 modifications initiated by Erg11p. It is the target of the fungicide fenpropimorph. In S. cerevisiae, this inhibition results in the accumulation of ignosterol, (ergosta-8,14 dien 3b-ol) (Fig. 1) . This indicates that downstream enzymes are inactive on sterols that retain the C14 0/15 double bond, and that ignasterol is not tolerated. It perturbs the membrane and inhibits uptake of glucose and pyrimidines. Mutations in ScERG24 confer resistance, and ScERG24 disruptants are aerobically viable, but dependent on increased Ca '' . CaERG24 was cloned by its ability to complement an S. cerevisiae erg24 mutant. Its disruption in C. albicans is viable, slow-growing, slightly resistant to azoles and nystatin, and hypersusceptible to cycloheximide, cerulenin, fluphenazine, and brefeldin A, suggesting increased permeability. Disruptants were unable to germinate and showed reduced virulence in a mouse disseminated candidiasis model [46] . These results indicate that CaErg24p is like ScErg24p and is a potential target for next-generation antifungals.
Mutations in or overexpressions of CaERG24 have not been published. However, its overexpression on our multicopy plasmid confers resistance to azoles; these transformants have not been tested yet for resistance to fenpropomorph (unpublished results). It is not obvious to us why overexpression of the C-14 reductase should confer resistance to inhibitors of C-14 demethylase; sterol analysis and permeability studies of these transformants are warranted.
ERG25 encodes C4-sterol methyloxidase, which, acting in concert with Erg26p, sequentially removes the two C4-methyl groups. Its disruption in S. cerevisiae results in sterol auxotrophy, indicating that the accumulated 4,4 dimethylzymosterol is not a tolerated membrane sterol. The auxotrophy can be suppressed, either by a second mutation in ERG11 or by azoles. In this situation, azoles actually promote growth of the erg25 mutant. The intermediate that accumulates is 24-methylenelanosterol, which apparently cannot be partially acted on by Erg3p to create a toxic sterol [47] . This suggests that another route to azole resistance is by inactivating mutations in ERG25. More intriguing is the notion that down-regulation of ERG25 should confer phenotypic resistance during azole exposure. The cloned CaERG25 gene is able to rescue erg25 mutants in S. cerevisiae [48] , but whether disruptants and azole suppression will be the same in C. albicans has not yet been determined.
Inhibitor studies suggest that blocking C4 demethylation will have similar effects in C. albicans. A natural antifungal agent, PF1163A derived from Penicillium , reportedly inhibits ScErg25p, since wild type cells are inhibited, but cells overexpressing Erg25p are not [49] . The agent also inhibits C. albicans, but resistance has not been reported [50] . Another agent, 6-amino-2-npentylthiobenzothiazole (APB), inhibits C. albicans in vitro and is effective in treating systemic candidiasis in mice [51, 52] . It blocks C4-demethylation in C. albicans and S. cerevisiae [53, 54] , but whether the specific target is Erg25p or Erg26p is not known.
HMG1 encodes the single C. albicans homolog encoding b-hydroxymethylglutarate reductase, the rate limiting and committed step in cholesterol biosynthesis in humans and the target of the statins such as Lovastatin and Zocor [55] . In S. cerevisiae, paralogous genes HMG1 and HMG2 each encode this activity and together are essential. The two enzymes are regulated differently [56, 57] . Overexpression of a truncated but active form of ScHMG1 resulted in accumulation of squalene, but near-normal levels of downstream intermediates, suggesting that Hmg1p is rate-limiting for the early portion of the pathway, but that regulation of ScERG9 restores normal levels in the latter pathway [58] .
Few studies have reported mutations in ScHMG1/2 that confer resistance to statins [59] ; none for CaHMG1 have been reported. However, Lovastatin inhibits growth of C. albicans and acts synergistically with FLZ to reduce the MIC (FIC 0.08), although this requires high concentrations of the statin and the synergy is media-dependent. What effects inhibitory concentrations of Lovastatin had on sterol composition, and whether the Lovastatin alone or in combination was fungicidal, was not reported. Lovastatin alone did not appear to cause changes in expression levels of HMG1 or selected genes in the ergosterol pathway, and changes in these genes after combined treatment approximated changes after FLZ alone [60] . Consistently, in S. cerevisiae, lovastatin is highly synergistic with azoles and results in inhibition of sterol esterification [61] . Perhaps the synergy results in part from a modest induction by Lovastatin of ERG3 [62] , which would potentiate azole effects.
Statins may be clinically useful in combination antifungal therapy, but a more potent but fungalspecific statin derivative of Lovastatin would likely be more useful and potentially fungicidal.
Amphotericin B (AMB)
This polyene antifungal forms a complex with a higher affinity for membrane ergosterol than for cholesterol, accounting for its specificity, and the complex forms a pore that permeabilizes the membrane, therefore is rapidly cidal [63, 64] .
Resistance in clinical isolates of C. albicans to AMB is rare, and it is difficult to obtain resistant mutants in vitro with single-step selection. While that is great news for clinicians, it has hampered understanding of the cellular response to AMB. Inhibition of ergosterol biosynthesis with azoles results in subsequent phenotypic resistance to AMB, consistent with the model that ergosterol is its primary binding site [65 Á/67] .
Consistently, mutations (ERG3, ERG11) that deplete C. albicans or C. glabrata of ergosterol result in AMB resistance in laboratory [25, 68] or patient isolates [69 Á/ 71] . Induction of C. albicans CDR1 by adriamycin resulted in tolerance to AMB [72] , but clinical strains that overexpress CDR1 are generally not resistant to polyenes.
Some studies implicate the fungal cell wall in AMBresistance. C. albicans shows increasing transient resistance, ''phenotypic resistance'', or PR, to AMB as it moves into stationary phase. This change is not seen if cell walls are removed with zymolyase or other wall-degrading enzymes, or weakened with mercaptoethanol [73 Á/75] . Ultrastructural changes in the periplasm and wall correlate with increasing PR [76] . We showed that intrinsic AMB-resistance in Candida lusitaniae is regulated by a high-frequency switching mechanism. Cells of most strains switched from resistant to susceptible, concomitantly from round to elongate in cell shape, at a frequency of about 1 per 100 to 1000 cells. Susceptible, elongate cells were hypersensitive to zymolyase, and zymolyase rendered resistant cells susceptible to AMB [77] . Consistently, in Aspergillus flavus, AMB-resistant mutants were isolated by step-wise selection. Mutant spheroplasts were as susceptible as wild type, but intact cells were resistant, suggesting that cell wall alterations conferred resistance [78] . Consistent with the notion that alterations in the wall confer AMB resistance, microarray analysis of an AMB-and FLZ-resistant derivative of C. albicans show upregulation of cell-wall maintenance gene PHR2 along with select ERG genes [79] .
Much of the AMB-resistance pathway is still unknown. Consistently, we recovered five different genes from our C. albicans overexpression library, whose overexpression confers resistance to AMB. Only one of these is wall-associated, one may be a stress-response sensor, and the rest have no associated functions to date.
Regulation of ergosterol biosynthesis genes
Studies of the regulation of ERG genes in C. albicans are just beginning, but are important in that resistance could evolve via mutation of ERG gene activators. Extrapolating from studies of S. cerevisiae, we expect that the pathway is feedback inhibited by ergosterol or other late sterol derivatives at the enzymatic and transcriptional levels [80, 81] .
Promoter/reporter fusion constructs in S. cerevisiae were used to ask which of the ERG genes were transcriptionally regulated in response to inhibitors of HMG1, ERG9, or ERG11 [62] . Several genes stood out as being strongly upregulated compared to other genes in the pathway. All inhibitors upregulated ERG12, ERG8, and ERG19 in the isoprenoid subpathway, and ERG9 and ERG2 in the sterol-specific latter pathway. ERG 10, HMG1, and ERG20 were upregulated by statins, and ERG11 and ERG6 were modestly upregulated by azoles. ERG3, ERG4, and ERG5 were downregulated by FLZ. In contrast, an earlier study showed dramatic induction of ScERG3 by statins or ketoconazole [82] .
ScErg9p, encoding squalene synthase, is the first enzyme in the pathway dedicated just to sterols as opposed to earlier points in the isoprenoid pathway. Therefore it should be and is a focal point of regulation, since sterols are needed in vast excess of other isoprenoid derivatives. ScERG9 is upregulated by defects in downstream genes ERG3, ERG7, ERG24 or by inhibitors (azole, zaragozic acid) and by heme activated protein transcription factors HAP1 and HAP2/3/4 [83] . More complex levels of regulation are probably also operative. For example, ScERG3 is upregulated by mutations in ScHMG1, ScERG2, ScERG4, ScERG5, and ScERG6 [84] . This result indicates more expression analysis is needed, and the complexity offers the opportunity for significant differences in regulation between species. Studies of the regulation of CaERG9 are not yet reported.
One of the pathways that branches from preCaERG9 ergosterol biosynthesis results in synthesis and secretion of farnesol, a derivative of farnesyl pyrophosphate. In vitro, farnesol acts as a quorum sensor, in that its gradual accumulation by growing cells inhibits the yeast-to-hyphal transition without itself being inhibitory [85] . Farnesol accumulation increases 8-fold upon inhibition of CaErg9p by zaragozic acid, even more rapidly after azole inhibition [86, 87] . The authors suggested that this accumulation is partly responsible for the fungicidal or fungistatic effects of the antifungals, and for their ability to inhibit biofilm formation, but this remains to be demonstrated.
Expression studies in C. albicans have generally confirmed expectations that negative regulation based on sterol levels is operative, since inhibitors or downstream mutations result in upregulation of several ERG genes. Which genes are upregulated depends on how the individual study was conducted. Mutants defective in ERG6 or ERG24 show increases in expression of ERG11, ERG7, and ERG25 [88] . In RT-PCR studies, azoles and terbinafine induced expression of ERG9, ERG11, ERG25, and ERG3 from 1 to 5 hours after exposure, and prevented downregulation of ERG1 and ERG7 [89, 90] . In a promoter-fusion study, ERG11 was induced by azoles and terbinafine after a lag period, suggesting that the induction resulted from the depletion of ergosterol occurring in the first 4Á/5 hours after exposure [91] .
Microarray studies are an attempt to get a handle on this complexity. In an older study, 24 h exposure to itraconazole resulted in upregulation of most of the ERG genes [92] . However, this study may be flawed in that it compared expression levels to parallel untreated 24 h cultures which were in post-log phase by that time. Baseline levels of the ERG genes would be reduced under those conditions, inflating the levels of the itraconazole-treated culture. More recent microarray studies have focused on comparing resistant to susceptible cultures, or comparing effects of very short-term exposures to azole. In the Sanglard microarray study, ERG3, ERG6, and ERG25 were upregulated 4 Á/6-fold in strains overexpressing CDR1, but were not upregulated by short-term exposure to fluphenazine [93] . In contrast, the ERG genes did not show major changes in expression among lineages that evolved resistance to azoles after in vitro selection, other than a 3-fold decrease in ERG1 in one of the adapted strains [94] . In step-wise selected azole resistant strains examined by Roger's group, only ERG2 showed an increase [95] . Since these microarray-bases analyses of different azole-resistant strains do not show common alterations in specific ERG genes, and also differ from similar studies in S. cerevisiae, where, for example, ERG8 and ERG13 are downregulated [96] , the implication is that they do not play pivotal roles in the resistant phenotypes. Alternatively, in individual strains, individual changes in ERG gene expressions may be important in the context of other mutations that are lineage-specific.
Despite the systematic analysis of ERG gene expression following exposure to antifungals, recent work has identified one of the regulators. CaUPC2, homologous to sterol uptake genes ScUPC2 and ScECM22, is important for ERG gene inductions and antifungal resistance [97] . Disruption of this gene, encoding a zinc finger transcription factor, confers hypersusceptibity to azoles, terbinafine, and lovastatin, as well as cell wallacting agents Nikkomycin Z and calcofluor white. Disruptants are unable to upregulate ERG2 or ERG11 in response to fluconazole, show depleted levels of ergosterol, and reduced ability to import labeled cholesterol. Thus, CaUPC2 may regulate expression of ergosterol biosynthesis and sterol uptake genes. Potentially, hyperactive point mutations in CaUPC2 could confer azole/terbinafine resistance. This study suggests that regulation of ERG genes is important in maintaining normal levels of susceptibility to antifungals, so it is not necessarily inconsistent with the mixed messages from microarray studies which suggest that there is no dominant pathway to antifungal resistance by overexpression or upregulation of specific ERG genes.
Identifying putative regulatory genes by homology to S. cerevisiae is not always so successful. ROX1 has been identified as a transcriptional repressor of ERG genes in S. cerevisiae, but its closest C. albicans homolog RFG1 is involved instead in filamentation [98] . However, these genes are not orthologous; their proteins share only a short region of homology, an HMG domain indicative only of a DNA binding protein, not of a specific function. A corresponding C. albicans gene, if it exists, will have to be discovered with a functional assay.
A short publication recently documented a 2.5-fold upregulation of ERG3 by disrupting EFG1, and makes the claim that resistance is the result of this upregulation [99] . EFG1 encodes a helix-loop-helix transcriptional activator which is known as a regulator of morphogenesis and virulence [100 Á/102] . This recent claim that overexpression of ERG3 mediates resistance is at odds with our results with the overexpression library, and with the expectation that overexpression of ERG3 should increase susceptibility, not resistance, to azoles, by increasing production of the toxic sterol intermediate (Fig. 1 ). While the publication does support that ERG3 is upregulated in EFG1 disruptants, it does not support the conclusion that the resulting resistance is mediated by ERG3, since expressions of hundreds of other genes were also affected by the disruption, and since expression of ERG3 was only monitored at a single time point in the absence of FLZ.
ERG gene overexpression study
Our laboratory has initiated a study on the effects of overexpression of CaERG genes on antifungal resistance. Each gene was amplified from a susceptible C. albicans genome by PCR and cloned into our high copy plasmid [22] . Recombinant plasmids were transformed into C. albicans, and tested for susceptibility in an agar-based assay. Overexpression of ERG1 resulted in terbinfine resistance without cross-resistance to FLZ, as expected. Likewise, ERG11 or ERG 6 overexpression conferred azole resistance, and ERG3 overexpression conferred hypersusceptibility (Akins et al. manuscript in preparation).
There were some surprises in this study. Overexpression of ERG24 unexpectedly conferred resistance, surprising since its disruption confers slight azole resistance [46] . Overexpression of CaPDR16 conferred hypersusceptibility, but was expected to confer resistance, since disruption of ScPDR16 confers hypersusceptibility [103] .
One might have predicted that overexpression of genes upstream of ERG11 would confer azole hypersusceptibility if they resulted in increased production of the toxic sterol. Alternatively, the overexpression might confer resistance if they resulted in increased levels of Erg11p. Neither was observed, since overexpression of Erg1p, Erg9p, and Erg20p had no effect on azole susceptibility. This suggests that they are not rate limiting steps in production of lanosterol, so that their overproduction does not increase lanosterol pools. Since upregulation of ScERG9 confers azole resistance [83, 104] , we may be witnessing another pathway difference between C. albicans and S. cerevisiae.
Efflux of antifungals as a resistance mechanism

ABC transporters
CDR1 and CDR2 are ABC transporters, transmembrane efflux pumps that use ATP to move a variety of small hydrophobic compounds out of the cell. These are the major efflux mechanisms of clinical significance in C. albicans. They are homologous to S. cerevisiae efflux pump PDR5 and were identified by their ability to complement pdr5 mutants [105, 106] . They are related to the transmembrane human P-glycoprotein encoded by MDR1. These genes arose by duplication of an ancestral gene containing one nucleotide binding domain (NBD) followed by a six-pass transmembrane domain (TM). Based on studies of human MDR1, one expects that the Candida pumps will work by binding of small hydrophobic substrate molecules to high affinity sites, probably within the plasma membrane in the cytoplasmic leaflet, which then pass substrate to a secondary site on the extracellular leaflet, from which it is released. Binding and movement of substrate will require binding and hydrolysis of ATP by the two nucleotide binding domains (NBD). A recent review models these expectations [107] . How such a broad group of structurally unrelated compounds can be effluxed by a single pump is still an open question.
Overexpression of CDR1 or CDR2 confers resistance to azoles including fluconazole, ketoconazole, miconazole, voriconazole, and itraconazole, and to terbinafine and cycloheximide. Overexpressing strains have increased abilty to efflux nystatin [108] , but this did not confer resistance to nystatin [109] . Based on clinical strains that overexpress CDR1 or CDR2 but are susceptible to posaconazole, one assumes that the latter is not an effective substrate [11] . Many other agents are apparently effluxed by CDR1 or CDR2, and it is clear that the two pumps have only partly overlapping specificities (reviewed in [107] ).
In S. cerevisiae, there are at least 31 genes encoding ABC proteins, 11 in the PDR family [110] . In the C. albicans genome, there are only six members of this family that have hallmark dual nucleotide binding domains (NBD), each followed by six transmembrane domains (Table 2 ). CDR1 and CDR2 are about Â/1500 amino acids long, 100 kb apart on chromosome 3, and are 83% identical and 91% similar [111] . Four other genes in C. albicans share extensive homology. CDR99 on Ctg19-10079 is the closest in sequence, 69% identical, 81% similar to CDR1, followed by CDR4 on chromosome 1 at 59% identical, 73% similar, CDR3 on chromosome 4 (53% identical, 68% similar), and SNQ1 on chromosome 6 (39% identical, 57% similar). CaO19.4531 has an additional seventh TM domain in the N-terminal half, and is only 24% identical, 42% similar to CDR1. ADP1 has a half-transporter structure with one NBD and a sixth transmembrane domain, which are 22% identical and 44% similar in this region to CDR1. Except for CaO19.4531, each member of this family has nearly identical patterns of TM domains. Each member also has highly conserved NBD domains (Fig. 2) . No other proteins in the C. albicans database show the conserved NBDs characteristic of this family.
Among the six C. albicans ABC transporters, only CDR1-4 have been functionally analysed, and only CDR1 and CDR2 are so far associated with azole resistance. Many lines of evidence argue that these two genes are major determinants of resistance in clinical isolates. For example, expression of these genes on a high copy plasmid in S. cerevisiae, in which endogenous ABC transporters were deleted, conferred high level resistance to azoles [106, 112, 113] . Deletion of CDR1 confers hypersusceptibility to azoles in C. albicans [114] . Overexpression of CDR1 and CDR2 is common among resistant clinical isolates [115 Á/118] and in laboratory isolates selected for azole resistance [94, 119, 120] , although some susceptible clinical isolates also overexpress CDR1 [118] . Deletion of CDR2 in C. albicans confers hypersusceptibility in strains already deleted for CDR1 [106] . Expression of CDR2 is elevated in revertants of hypersusceptible mutants in which CDR1 had been disrupted [121] .
Heterologous overexpression in S. cerevisiae of CaCDR3 did not confer a resistant phenotype. Neither CDR3 or CDR4 is induced by FLZ. Disruption of CDR3 or CDR4 did not confer hypersusceptibility [122, 123] . Therefore it appears that these genes are not involved with resistance. However, these disruptions are inconclusive, and the implication that neither gene functions in multidrug resistance is premature, pending analysis of disruptants created in a strain disrupted for CDR1 and CDR2, and pending overexpression analysis in C. albicans. The NBDs are on the amino-side of the TM domains, and each has a highly conserved ABC signature motif with flanking Walker A and B motifs [123] . CDR1 has the fungus-specific cysteine in the conserved Walker sequence of NBD1 instead of the invariant lysine found in non-fungal ABC transporters [ Fig. 2] . Replacement of this cysteine with a lysine in CaCDR1, placed in a S. cerevisiae hyperexpression system, diminishes ATPase activity and confers hypersusceptibility to antifungals without altering protein localization or stability. Replacement of the conserved lysine in the Walker box of NBD2 has similar, but not identical effects, from which the authors conclude that the two NDBs have different functions [124] . The authors, however, have not dismissed an alternative explanation, that the two might have identical functions that are not evident since the mutations introduced into each are not equivalent. Site-directed mutatagenesis of C193 or K901 in Walker box 1 and 2 (outside the most conserved sequences shown in Fig. 2 ) diminishes ATPase activity, whereas changes at other conserved positions in the boxes do not [107] .
Another structure-function study shows that a mutation in transmembrane domain 11, converting threonine at position 1351 to phenylalanine, blocks resistance to antifungals and FLZ efflux, without altering ATPase activity, nucleotide/substrate binding, or protein localization and stability [125] .
Six transmembrane domains are on the carboxy side of each NBD in the CDR family of transporters. Based on studies with human Mdr1p, one expects that some drug-binding sites in Cdr1p would occur in the carboxy-terminal transmembrane domain 12. Consistently, deletion of this domain from CDR1 and expression in a multicopy plasmid in S. cerevisiae pdr5 mutant resulted in loss of resistance relative to intact cloned CDR1. However, the loss was selective and drug-dependent. For example, CDR1-mediated resistance to azoles, oligomycin, chloramphenicol, and benomyl was retained in the DTM12 strain, but resistance to cycloheximide, anisomycin, and nystatin was lost. The DTM12 strain retained the CDR1-dependent ability to efflux estradiol and to hydrolyze ATP [108] . Point mutations in TM10 of ScPDR5 alter substrate (azole) and inhibitor (FK506) specificity [126] ; effects of analogous mutations in CDR1/ 2 have not yet been reported. However, site-directed mutagenesis of CaCDR1 overexpressed in S. cerevisiae showed that some mutations in TMS11 or in the sequence between Walker box A and signature C in NBD1, conferred hypersusceptiblity to anisomycin, cycloheximide, fluconazole, miconazole, and nystatin. Other mutations in TMS6 or in the sequence between Walker A box and signature C sequences in NBD2 conferred hypersusceptiblity to a subgroup of these substrates. One mutation in TMS6 caused mislocalization of the protein unless the cell was grown in cycloheximide [107] . Clearly, many more site-directed mutations are needed to complete this story.
The fluorescent dye rhodamine 6G has been used to monitor efflux via CDR1, since the dye has been shown to accumulate in FLZ-susceptible cells not overexpressing CDR1, and conversely to move into the supernatant in FLZ-resistant cells overexpressing CDR1 or CDR2, but not MDR1. This efflux is energy and temperature dependent, as expected of an active transport mechanism [127] . It had been assumed that the dye was directly effluxed by Cdr1p, but could have been an indirect mechanism activated by Cdr1p activity. Direct involvement with substrates has now been demonstrated. Shukla et al. showed that a heterologously overexpressed CaCDR1-GFP pump binds to photoaffinity reagents known to bind to human P-glycoprotein. Binding of these reagents is competed out by putative Cdr1p substrates nystatin and miconazole [128] . Similarly, Gauthier et al. have shown that Cdr1p and Cdr2p cross-link to a photoaffinity reagent derived from rhodamine 6G, showing their direct involvement in efflux and enabling the localization of binding sites. Overexpression of these proteins in S. cerevisiae conferred resistance to FLZ, ketoconazole, and itraconazole, and showed increased efflux of rhodamine 6G [129] , as predicted from earlier work [106, 113] . They went on to show that the photoaffinity reagent IAARh123, known to cross-link to human MDR1, specifically cross-linked to both Cdr1p and Cdr2p. N-and C-terminal ''halves'' of CDR2 could bind rhodamine 6G independently, although both halves were required for resistance. Cells expressing CDR1 were hypersusceptible to FK520, an immunosuppressant shown to compete for binding sites on human MDR1, whereas cells overexpressing CDR2 were resistant to FK520. Furthermore, cells expressing CDR1, but not CDR2, showed strong synergy between fluconazole and FK520 at subinhibitory doses. Similar results were reported by others [130] . Cells expressing CDR2, but not CDR1, were hypersusceptible to hydrogen peroxide and resistant to diamide [129] . Thus, there are clear differences between these two highly homologous pumps.
More recently, specific overexpression of CDR1 in C. albicans has confirmed its importance in conferring multidrug resistance in its normal host [109] . Its overexpression was achieved by creating a fusion of the N-acetylglucosamine-inducible, glucose repressible HEX1 promoter to the coding region of CDR1. This construct was cloned into a shuttle plasmid and transformed into C. albicans strain CAI4. Transformants showed N-acetylglucosamine-dependent increases in CDR1 mRNA and CDR1p antigen, and rhodamine 6G efflux, during 3 hours of induction, with no corresponding increases in glucose grown cells. Cells grown in N-acetylglucosamine showed increased resistance to typical CDR1 ''substrates'', including azoles and terbinafine, confirming that the elevated level of CaCdr1p had the same effect in C. albicans as it did it S. cerevisiae. But surprisingly, transformants were also resistant when grown in glucose when the cloned gene should have been repressed. The differences in induction experiments and in vivo resistance were not adequately addressed by the authors, by including extended time points in their mRNA and antigen assays, to determine if there were corresponding increases in CDR1 in glucose cultures.
Immunosuppressant FK520 is known to be synergistic with azoles to produce a fungicidal effect. This synergy is due to direct competition of FK506 with FLZ for CDR1-mediated efflux, since: (1) cells overexpressing CDR1 accumulate FLZ in the presence of FK506, but not so if they overexpress a mutant allele, T1351F, that does not bind FK506; and (2) cells overexpressing CDR1 are hypersusceptible to the combination, but those overexpressing the T1351F mutation are not [125] . In other words, residual FK506-resistant efflux of FLZ by the mutant is sufficient for low-level resistance. This argument is somewhat weakened by the observation that the level of FLZ accumulation in the mutant is only marginally lower than in controls not expressing CDR1 at all. Furthermore, it is controversial, since other studies indicate that the immunosuppressants act by inhibiting the calcineurin-mediated stress response pathway. Another explanation for these observations might be that a high level of CDR1-mediated efflux is detrimental to cells with an activated calcineurin pathway.
Cdr1p and the related Pdh1p in C. glabrata are homologous to and presumably efflux antifungals like C. albicans CDR1. There is evidence that the C. glabrata pumps may be regulated by phosphorylation [131] . Phosphorylation of CaCdr1p may also be required for its function, since dephosphorylated membrane fractions containing CaCdr1p show reduced ATPase activity [131] , and also since serine to alanine mutations at major sites of phosphorylation, S307 and S484, diminish rhodamine 6G efflux. Double mutants are completely defective in efflux [132] . Noteworthy is that all of these modifications are occurring in the heterologous hyperexpression system in S. cerevisiae. It remains to be determined whether phosphorylation of either pump occurs in C. albicans, and how that affects their function, or is regulated.
Studies cited above suggest that resistance in clinical isolates to azoles, largely mediated by overexpression of CDR1/2, might be overcome by simultaneous treatment of ABC inhibitors such as FK506, FK520, or a propafenone GP382 [125, 129, 130] . From a clinical perspective, this approach may be limited, since the inhibitors appear to target only Cdr1p, not Cdr2p, and since resistance mutations arise at high frequency. Disulfiram is another candidate for a CDR antagonist, since it appears to inhibit human MDR1 [133, 134] . Shukla et al. [135] showed that disulfiram treatment of a CaCdr1p-enriched plasma membrane fraction isolated from S. cerevisiae results in inhibition of its ATPase and nucleotide binding activities. They further show that disulfiram acts synergistically with antifungals that are substrates of CDR1 to inhibit the CDR1 overexpressing strain. The authors, however, imply that disulfiram reverses CDR1-mediated resistance by specific reactions with CDR1. The agent likely inhibits activities of many enzymes, not just CDR1, the only activity investigated in the study. Since disulfiram alone is fungicidal at only slightly higher concentrations than when used in the synergy study, the conclusions are tenuous. This potential lack of specificity may be a deterrent to its clinical use, as is its lack of fungicidal or fungistatic effects on C. albicans in ex vivo blood cultures, even at much higher doses (unpublished observations).
Regulation of CDR1/CDR2 genes
Regulatory sequences
Understanding how CDR1 and CDR2 are regulated is clinically important, since in resistant isolates, these genes and others are often upregulated together, suggesting that resistance is due to mutations in regulatory genes.
Studies in S. cerevisiae highlight the complexity of regulation of multidrug resistance genes. ScPDR1 and ScPDR3 encode the master regulators in the PDR network. The proteins are Gal4p-like Zn(II)2Cys6 transcription factors which form homo-and heterodimers that are constituitively nuclear and bind to their target response element (PDRE, consensus 5'-TCCGCGGA-3'). Differing numbers and combinations of binding sites upstream of individual PDR target genes determine whether PDR1, PDR3, or both, are required for activation or repression of each gene. Point mutations in the regulators can cause hyperactivation as well as inactivation. Some target PDR genes are also controlled by stress-induced regulators encoded by YAP1, YAP2, and MSN2/MSN4 [110] .
How are the C. albicans ABC transporter genes regulated? CDR1 is expressed at all phases of growth, but declines about 2-fold during midlog phase. It is dramatically induced in a 60 min time frame by progesterone, b-estradiol, miconazole, nystatin, vinblastine, and heat shock, but less dramatically by cycloheximide, vinblastine, and FLZ [136] . Using an integrated CDR1/GFP fusion strain, others showed that FLZ does induce CDR1 expression after sustained exposure (e.g. overnight), and the induction is concentration-dependent and reverses upon withdrawal of FLZ. In this system, azoles in general induce CDR1 from 6-to 8-fold, cycloheximide 6-fold, calcofluor and 5-fluorocytosine about 2-fold, while amphotericin B and peroxide at subinhibitory concentrations did not induce CDR1 [137] .
Two laboratories have scrutinized the promoter and upstream regulatory sequences of CDR1. Using a CDR1/luciferase fusion on a multicopy plasmid, Puri et al. identified the transcript start site and defined the promoter region within (/345, with a distal miconazole response element at (/847 to (/1147, which contained an AP-1 sequence that showed DNA-protein binding activity. This 1 kb region contained several upstream activating and silencing domains [138] . In a follow-up, the group identified sites protected from DNaseI within the (/289 region. Mutation of one of these resulted in enhanced transcription, thus identifying it as a negative regulatory element (NRE). The NRE was used to affinity purify a DNA binding protein, not yet analyzed. The sequence of the NRE was CCAACTGATT-GAAAC. A different protected sequence at (/243 to (/234, TCTTTTCCACT, was a basal regulatory element BRE, needed for low level transcription, since mutating it decreased transcription [139] .
Using a CDR1/luciferase fusion in an integrative plasmid, de Micheli et al. analysed the upstream regulatory region. They defined a 21 bp drug-response element (DRE) at Á/480 Á/ (/420, with a homolgous DRE in CDR2 at Á/240 Á/ (/180 (CGGA(A/T)ATCG-GATATTTTTTTT). These sequences were necessary and sufficient for inductions mediated by steroid hormones, amorolfine, terbinafine, and fluphenazine, but again, not by FLZ. Both DREs showed specific DNA-protein binding activity. In addition, CDR1 but not CDR2 contained a BRE ( (/860Á/(/810) needed for uninduced low level transcription [140] . More recently, they have shown that 40 of 42 genes that are upregulated in response to fluphenazine have the upstream DRE element [93] .
Karnani et al. [141] have also identified a steroid response region in the Á/696Á/(/521 region of CDR1. Two elements within this region, SRR1 and SRR2, confer steroid inducibility on CDR1 or heterologous recombinant promoters, and show specific DNA-binding from nuclear extracts of steroid induced C. albicans. SRE1 responds to progesterone, whereas SRE2 responds to progesterone and -oestradiol. Disruption of genes encoding regulatory proteins involved in morphogenesis, (SSK1, EFG1, TUP1, CPH1, NRG1, TPK1, or RAS1) did not result in a clear definition of which activators are interacting with the SRR elements. Comparing promoters of other genes regulated by steroids, a consensus sequence was found that may represent binding sites for the activator: (/661 Á/ (/165-AAGAA (/13 to152 bp-CGCAA (/21 to 68 bp-ATTG-G (/603 to (/84.
Regulatory proteins
A definitive study reporting TAC1 as an important transcriptional activator of CDR1 was recently reported [142] . This gene was identified by its Zn(2)-Cys(6) finger domain and its locus, linked to mating type. Its nuclearly-localized product interacts with the drug-response element (CGG triplets) in the promoters of CDR1, CDR2, and other genes. Its disruption results in hypersusceptibility to azoles and inability to upregulate CDR1 or CDR2 by fluphenazine. Tac1p binds to DRE elements upstream of CDR1 and CDR2. A co-dominant point mutation in TAC1 confers constituitive upregulation of CDR1 [142] and is consistent with the observation that homozygosity at the linked mating type locus is strongly correlated with azole resistance [143] .
Potential activators of CDR1 were also screened by integrating a hybrid CDR1 promoter/lacZ fusion into S. cerevisiae, then transforming with a C. albicans library on a multicopy plasmid. This identified CaNDT80, homologous to a meiosis-specific transcription factor in S. cerevisiae with a novel DNA binding motif. Disruption of CaNDT80 confers hypersusceptibility to azoles and decreases the azole-induced expression of CDR1 [144] .
It is possible since Tac1p binds to DRE elements, that Ndt80p binds to the basal regulatory element (BRE) in the CDR1 promoter, identified by de Micheli et al. [140] . However, the putative binding site for Ndt80p, based on its S. cerevisiae homolog (GNCR-CAAA(A/T), does not correspond to the region defined as the BRE by either laboratory. Therefore, data from the three laboratories suggests that three activators may be required for CDR1 expression, with Tac1p being the limiting factor. Verification of this will require identification and mutation of the binding site(s) for Ndt80p and disruption of the gene encoding the DNA-binding protein that binds to Gaur et al. 's BRE [139] .
Older approaches to analysing the candidate regulators of resistance genes in C. albicans have been to identify and clone homologs of regulatory genes in S. cerevisiae, then transform S. cerevisiae strains, deleted for those genes, with the cloned C. albicans homolog. This is a powerful method, but has its limitations, as the following examples show. In S. cerevisiae, yAP1 regulates expression of a large number of genes in response to oxidative stresses and to azoles. Notably, it upregulates ScFLR1, an MFS protein, to confer resistance to FLZ. The C. albicans homolog CAP1 complements yAP1 function in deletion strains [145] . However, overexpression of CAP1 in C. albicans does not confer FLZ resistance, but downregulates MDR1 [146] . ScPDR1 and ScPDR3 regulate expression of many genes including ABC transporter PDR5 [147 Á/ 150], the homolog of CaCDR1, which confers FLZ resistance when overexpressed [151] . C. albicans genes have been identified that complement PDR1/3 deletion strains and are PDR5-dependent for FLZ resistance. One of these, FCR1, was identified as a Zn 2 C 6 type zinc finger regulatory protein like PDR1/3. However, deletion of this gene in C. albicans confers hyperresistance to FLZ, the opposite of that expected from S. cerevisiae [152] . A second complementing gene, FCR3, encodes a leucine zipper regulatory protein that upregulates PDR5. Its role in C. albicans is not yet reported [153] .
Regulation of expression by PDR1 in S. cerevisiae requires other proteins that regulate the activity of the transcription factors. ScPDR13 in S. cerevisiae was discovered by screening a multicopy plasmid library for transformants that were cross-resistant to oligomycin and cycloheximide, normally mediated by two different ABC transporters YOR1 and PDR5, respectively. Both transporters were upregulated and required library transformants that overexpressed PDR13 and were PDR1-dependent. Other observations suggest that PDR13, a chaperone, acts by binding to and enhancing Pdr1p in its activation of select gene targets [154 Á/158] . Considered together, it appears that activation of many stress-related transcription factors may be dependent on the interaction with individual chaperone subunits, which in turn require some form of modification, presumably stress-related, that frees these subunits from their normal location and function. It has not yet been determined whether an identified CaPDR13 homolog plays a similar role in resistance in C. albicans.
Drug efflux and membrane composition
Human P-glycoprotein is enriched in cholesterol and sphingolipid-rich microdomains, rafts and caveolae, which are more rigid than the rest of the plasma membrane, and which increase dramatically in MDR human cells. There is controversial evidence that its efflux activity is responsible for translocation of phospholipids and cholesterol from the inner to the outer leaflet of the plasma membrane [159] . Experimentally induced movement of P-glycoprotein from rafts to non-raft membrane, e.g. by cholesterol depletion, results in a reduction in efflux capacity [160 Á/162] .
There is evidence that yeast membrane proteins cluster into distinct raft microdomains in the ER for transport to the plasma membrane, an area that needs much more study [163 Á/169] . Applying this to Candida , Dogra et al. [170] have shown that the plasma membrane of C. albicans is asymmetric with repect to phospholipids, with phosphatidylethanolamine predominantly (96%) in the cytoplasmic leaflet. Disruption of CDR1 and CDR2 results in a further decrease in the amount of this phospholipid in the external leaflet, suggesting that the pumps, in an additive fashion and like human MDR1, may be responsible for the energy-dependent externalization of this aminophospholipid, hence act as a floppase.
Since the fluidity of the membrane in the vicinity of human MDR1 has been shown to affect its activity, Smriti et al. [171] expressed CDR1 in isogenic strains of S. cerevisiae with various erg mutants that generally have increased membrane fluidity. Mutants erg2 and erg3 , with more fluid membranes, showed increased floppase activity and decreased accumulation of labeled FLZ, whereas erg4 mutants, with less fluid membranes, showed decreased floppase activity and near normal FLZ accumulation. Differences in susceptibility to FLZ were not impressive, but in this study, the host strain still had endogenous ABC transporter genes that increased baseline susceptibility.
Mukhopadhyay et al. [172] later showed that erg6 and erg16 mutants were hypersusceptible to azoles except FLZ, to terbinafine, and other agents, and that these mutants had more fluid membranes. These cells, when de-energized, accumulated more rhodamine 6G or labeled FLZ than controls, suggesting increased passive transport due to increased permeability. Increases in membrane fluidity alone are not likely explanations for resistance, since cells in which fluidity had been increased by benzyl alcohol were not resistant. However, membrane sphingolipid from the erg mutants, with depleted sterols, were more readily extracted, indicating a disruption in the interactions in the membrane that normally hold sphingolipid in place. This effect was eliminated by growing the mutants in ergosterol. Consistently, with inhibition of sphingolipid biosynthesis with fumonisin B1, wild type cells became hypersusceptible to multiple antifungals and showed poor efflux of rhodamine 6G without increases in membrane fluidity. Disruptions to ergosterol or sphingolipids resulted in poor surface localization of Cdr1p-GFP hyper-expressed in S. cerevisiae missing its major ABC pumps [172] . Similar results were obtained when expressing CDR1, but not MDR1, in S. cerevisiae [173] . These data suggest that it is not the altered fluidity of the plasma membrane per se that increases susceptibility, nor the associated increased permeability, but rather the disruptions to ergosterolsphingolipid rich raft domains, which appear to be essential for CDR1 localization and hence function.
In S. cerevisiae, deletions of various non-essential ERG genes results in altered membrane sterols and increased drug susceptibilility. Although it is generally assumed that this results from increased permeability, more recent study shows that it can be accounted for by decreased activity of Pdr5p. This decrease is largely due to partial mislocalization of the pump and is not directly correlated with differing fluidities among individual erg mutants. Efflux is reduced most by ERG4, almost as defective as PDR5 disruptants, with ERG4 !/ ERG6 !/ ERG2 !/ ERG3 [45] .
In a C. albicans strain selected for resistance to gradually increasing concentrations of FLZ, and overexpressing CDR1, CDR2, and ERG11, the membranes were increasingly fluid, and had less ergosterol and reduced externalization of phosphatidylethanolamine [174] . The authors suggest that these changes may contribute to resistance, perhaps by activating efflux. Alternatively, they may be a consequence of increased efflux due to the elevated levels of the pumps.
Efflux by major facilitators
CaMDR1, formerly BEN1, is a major facilitator (MFS) protein that is specific for FLZ among the azoles, not to be confused as a homolog of human MDR1, which is an ABC transporter. Major facilitators are proton antiporters whose energy derives from proton gradients established by independent proton-translocating ATPases. These transmembrane proteins typically confer resistance to inhibitory substances, and are found in bacteria, yeasts, and man. In S. cerevisiae, there are at least 23 such genes, some having 12, some having 14 transmembrane domains [175] . In C. albicans, there are no genes with strong similarity to MDR1, but there are seven related MFS proteins, all about 30% identical, 50% similar (Table 3) . Extrapolating from S. cerevisiae homologs, these proteins may be located in the plasma membrane and efflux polyamines and in some cases antifungals. However, only one of these, FLU1, has been analysed in relation to resistance (discussed below).
CaMDR1 apparently is induced by and effluxes a partially overlapping set of hydrophobic compounds compared to the CDR proteins: benomyl, methotrexate, cycloheximide, benztriazoles, 4-nitroquinoline-Noxide, FLZ, and sulfometuron methyl [176 Á/178] . Its disruption confers hypersusceptibility in clinical isolates whose resistance is associated with elevated expression of MDR1 [179] . Therefore, MDR1 is a major factor in resistance in clinical isolates to FLZ. However, disruption of MDR1 in FLZ-susceptible strains has no effect, undoubtedly because the gene is not expressed under normal circumstances in these strains [180] . . . a lesson to be remembered when analysing gene disruptions in general. In one report, disruption of MDR1 did not increase susceptibility above the levels conferred by disruption of CDR1 [181] .
Little is known about MDR1 regulation, except that it is not induced by exposure to FLZ, but is upregulated by benomyl and apparently by mutation in a trans regulatory factor in some FLZ resistant strains [116, 182, 183] . Its closest homolog in S. cerevisiae, FLR1 (Table 3) , shares many of the same substrates and expression patterns. FLR1 regulation is induced dramatically but only transiently after exposure to benomyl. Once adapted to growth, the gene is downregulated. In S. cerevisiae, yAP1 regulates expression of a large number of genes in response to oxidative stresses and to azoles [175] . Notably, it upregulates FLR1 to confer resistance to FLZ. The C. albicans homolog CAP1, complements yAP1 function in deletion strains [145] . However, overexpression of CAP1 in C. albicans does not confer FLZ resistance as expected, in contrast, it downregulates MDR1 [146] .
C. albicans undergoes adaptive growth responses to FLZ as does S. cerevisiae, and these are favored by acidic media [184] . By analogy to FLR1, this suggests a role for MDR1, despite its apparent lack of induction by FLZ. The earlier studies discussed above may have missed the hypothetical, transient up-and downregulation. Assuming nonetheless that transient induction or activation of MDR1 is responsible for short-term adaptive growth in FLZ, the data invite the speculation that once intracellular FLZ concentration is reduced by efflux, a second mechanism is responsible for the more enduring capacity for growth, despite FLZ at concentrations that maintain ergosterol depletion [184] and (unpublished observations).
FLU1
Another multidrug transporter in the MFS class is encoded by FLU1 (Table 3) and was identified by its ability to restore resistance to fluconazole and cycloheximide to S. cereviseae pdr5 mutants. Like MDR1, this resistance did not extend to the other azoles. Its disruption in C. albicans only resulted in slight hypersusceptibility to FLZ, and a more pronounced hypersusceptibility to mycophenolic acid. The expression levels of this gene did not vary between susceptible and resistant matched pairs of a small number of clinical isolates. However, these isolates were not analyzed before and after FLZ exposure, thus it remains possible that resistant isolates had mutations that allowed more rapid or higher levels of upregulation only following exposure. No changes in labeled FLZ accumulation could be shown in FLU1 disruptants, whereas increased accumulation was seen CaO19.7148 (7) 29 (48) 43 (59) UNKNOWN Á/ CaO19.7974 (3) 27 (49) 31 (51) UNKNOWN TPO3 CaO19.4737 (1) 33 (52) TPO3 61 (74) UNKNOWN POLYAMINE TRANSPORT
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CaO19.9705 (6) 32 (52) 35 ( in CDR1 disruptants [181] . The effects of FLU1 disruption in a CDR1/CDR2 disruptant, or of FLU1 overexpression on accumulation in the S. cerevisiae FLU1/pdr5 strain or in C. albicans, were not reported. Thus, it remains unknown whether FLU1 can contribute to resistance. Considering the similarities among all the MFS transporters in Table 3 , it may be that yet other genes contribute to resistance. It should be emphasized that there are clinical isolates whose resistance seems to result from efflux mechanisms not attributable to CDR1, CDR2, or MDR1 (next section).
Evidence that resistance in clinical isolates of C. albicans is complex
In vitro evolution of FLZ resistance
In vitro ''evolution'' studies looking at the rise of FLZ resistance among populations of yeasts have been done for S. cerevisiae and C. albicans. This approach asks what types of mutation give rise to FLZ resistance when selecting among a population of cells in culture, not individual cells on agar. This imposes an extra criterion, since the resistant mutants must also retain some degree of fitness or be overgrown by more fit resistant mutants.
In S. cerevisiae, the outcome depended on the type of selective pressure. When using a single-step selection at a high FLZ concentration (128 mg/ml), mutants were repeatedly isolated that had recessive mutations in ERG3, which also resulted in the overexpression of ERG11. Such an outcome would not be expected in diploid strains of S. cerevisiae or in the diploid C. albicans. A global screening of all individual gene deletion strains showed that defects in many genes other than ERG3 result in FLZ resistance (sterol metabolism genes ERG6, ERG28, OSH1, SCS2, and eight other genes). These mutant genes did not arise in the mutant selection experiment because they are unfit. In contrast, in a second step-wise selection for resistant mutants, initially at 16 mg/ml, then 32 mg/ml, then finally at 128 mg/ml, a semi-dominant mutation in PDR1 was repeatedly isolated. This mutation arose early on in the selection process and was followed by a single, second mutation in an unknown gene, which increased the MIC. The PDR1 mutation resulted in overexpression of ABC transporter genes PDR5 and SNQ2, but not in the major facilitator gene FLR1 or consistently in ERG11 [119] .
There are two lessons to be learned from this study; both underscore the complex nature of azole resistance. First, many genes can potentially mutate to confer azole resistance. Second, among individual populations, the mutation responsible for the resistance can vary, and depends on the type of selective pressure. Extrapolating in vivo selection which potentially introduces more uncharacterized selective pressures than in vitro, could further impact the types of resistance genes that could predominate in individual patients.
In a second population-based selection for FLZ resistance, this time in C. albicans, the outcome was more complex. Again, individual cultures evolved differing patterns of resistance as FLZ concentrations were increased incrementally. Overexpression of CDR1, CDR2, MDR1, and ERG11 were episodic, as were other mutational changes [120] . Resistance, once established, was stable in the absence of selection for many generations as were the levels of overexpression. Microarray analysis of these in vitro evolving populations showed two patterns. In one, overexpression of CDR2 was predominant. In the second, overexpression of MDR1 was the major change, occurring either early or late in the evolution of stable resistance, along with changes in many other genes associated with oxidative stress or lipid metabolism. Clinical isolates showed genomic patterns in line with those that evolved in vitro [94] .
Independently, C. albicans was selected on gradually increasing concentrations of FLZ. Isolates along this time course showed incremental increases in expression of CDR1, CDR2, and ERG11 [174] . The take-home lesson from this approach is that genetic alterations that result in FLZ resistance occur incrementally and involve potentially many genes.
In vivo evolution of FLZ resistance
Comparing resistance genes among sequential isolates recovered from the same patient, that have decreasing susceptibility to FLZ, is an in vivo version of the in vitro evolution studies discussed above. Their story is much the same. Development of resistance occurs incrementally, with contributions from mutations in several known genes and most likely in genes yet to be discovered.
In a study of sequential matched isolates from OPC patients, development of FLZ resistance was complex [115] . For example, overexpression of only CDR1 conferred only moderate FLZ resistance in isolates from one patient, whereas similar levels expression of CDR1 in isolates from a different patient moderate resistance in some isolates, or very high resistance in other isolates, without any other apparent changes in CDR2, MDR1, or ERG11. Progression to higher resistance in a third patient did not involve increased expression levels of CDR1, CDR2, MDR1, or ERG11, therefore either resistant point mutations occurred in one or more of these genes or a different mechanism was used that did not involve these genes. The efflux genes are clearly important in resistance but do not tell the whole story. Moderate increases in some genetic backgrounds is apparently sufficient for resistance, but not in others. The question remains, what genetic differences contribute to this effect?
In a second study, serial isolates from an HIV patient had sequential alterations that were correlated with gradual increases in MICs to FLZ. Initial increases in MDR1 apparently resulted in moderate MICs, followed by several alterations in ERG11, and finally by increases in one of the CDR genes, to generate fully resistant derivatives [116] .
A third study of 4 FLZ-resistant C. albicans strains isolated from HIV patients again emphasizes that there are still unknown resistance mechanisms involved in resistance in clinical isolates. All four isolates showed reduced accumulation of labeled FLZ, but only two of these showed increased levels of CDR1 and CDR2 expression. The other two isolates presumably use an unknown efflux mechanism, or suppress uptake [117] .
A fourth study, which compared large numbers of unmatched clinical isolates, supports the argument that azole resistance is complex and not yet defined. The study compared expression levels and sequences of a large collection of clinical isolates, 50% FLZ resistant and 50% susceptible. Overexpression of CDR1 and CDR1 were common among the resistant isolates, overexpression of MDR1 was less common, and overexpression or mutation of ERG11 was not correlated with resistance. However, a significant percentage of susceptible isolates also overexpressed these genes. The authors concluded that molecular-based assays for resistance using these genes was not sufficiently predictive, and that other mechanisms and mitigating genetic factors need more study [118] .
Perhaps the most rigorous study of azole resistance in clinical isolates used RT-PCR to establish a baseline of expression levels of ERG11, CDR1, CDR2, and MDR1, relative to control genes, among FLZ-susceptible clinical isolates [11] . They then compared these levels to those found in 38 resistant isolates, considering whether these were resistant to FLZ, voriconazole, or posaconazole. Only one isolate was resistant to posaconazole. Consistent with some of the earlier studies, overexpression of ERG11 and MDR1 was not common among resistant isolates. CDR1 was overexpressed in less than half of the isolates, whereas CDR2 was overexpressed in all but three resistant clinical isolates. However, CDR2 was also overexpressed in some susceptible isolates. Resistant isolates were more polymorphic in ERG11 sequences than susceptible isolates, and seemingly fewer mutations were needed for FLZ or voriconazole resistance than for posaconazole resistance. However, the test for whether these mutations were responsible for resistance was to clone them into a multicopy plasmid and transform them into S. cerevisiae to confer reduced susceptibility. Despite controls, this assay is suspicious in that overexpression of even wild type ERG11 sequences in C. albicans confers high-level resistance (unpublished observations). This study is also limited in that it does not consider point mutations in CDR1/CDR2 genes. Furthermore, it only looked at expression levels of strains in the absence of azoles, therefore potential differences in responses of resistant strains to azoles are overlooked. Despite these limitations, the study indicates that it is likely that multiple mutations, including those affecting CDR2 or CDR1 expression and ERG11p binding to azoles, are responsible for in vitro resistance among clinical isolates.
Karababa et al. performed a thoughtful and careful analysis of gene expression using microarrays, comparing genes that were induced or repressed in a susceptible lab strain incubated in fluphenazine to induce CDR1 or in benomyl to induce MDR1, to genes altered between matched pairs of clinical isolates overexpressing either CDR1 or MDR1 [93] . In each case, multiple genes in addition to CDR1 or MDR1 were altered. By comparing these sets of genes, they identified the subsets of changes common to drug-exposed susceptible strains and resistant versus susceptible clinical strains. Comparing fluphenazine-exposed susceptible to CDR1-expressing resistant strains, including CDR1 (8-fold overexpression) and CDR2 (25 Á/40-fold overexpression), upregulation of heat shock protein HSP12, glutathione peroxidase GPX1, and potential lipid transportase RTA3. Interestingly, overexpression of ERG3, ERG6, and ERG25 was unique to the clinically resistant strains. The group further shows that comparisons of microarray results from other laboratories are useful in defining common subsets of genes that respond similarly to different types of stress, allowing much needed focus on a manageable number of genes to analyse in more detail. The main limitation of this study, imposed by the complexity of microarray analysis, and the amount of labor and expense involved, is that exposed susceptible strains are only examined at a single time after exposure to the antifungal agent. Thus, clinically resistant strains may be expressing a broader range of genes than exposed susceptible cells, but the two might have more in common given longer exposure times.
Many of the genes induced in MDR1-expressing clinical resistant isolates encoded enzymes in the aldo-keto reducatase family (IFD and related genes); these were not seen among induced genes in the CDR group [93] . Consistently, some of these genes were detected independently in two studies using a proteome approach, but again only in strains overexpressing MDR1 [185, 186] . One of these genes, YPR127, was altered both by overexpression and disruption, without effect on susceptibilities to azoles or oxidative stress. This serves as a reminder that many genes that are coregulated with resistance genes may not be important or limiting for a normal response to drugs or for resistance in clinical isolates.
Phenotypic resistance and tolerance
The implication of PDR1/3 mutants in S. cerevisiae, and of clinical resistant isolates that overexpress CDR1 and CDR1, is that mutations occur in regulatory genes in C. albicans that give rise to stable resistance in clinical isolates. Phenotypic or adaptive resistance is not mutation-based, but is defined as a reversible, regulated alteration in phenotype which allows growth in concentrations of antifungal drugs that were inhibitory prior to the alteration. This is likely due to upregulation or activation of activators, which are then downregulated once selective pressure is removed; phenotypic resistance may involve other genes in addition to the CDR genes. Tolerance is a term used somewhat loosely here to mean a static response in which the organism survives at inhibitory concentrations but cannot grow, hence is not resistant or phenotypically resistant. C. albicans is tolerant of azoles, since they are not fungicidal under most conditions. Tolerance more traditionally is used to describe a decreasing susceptibility to an agent after repeated exposures, but in this context has come to mean the opposite of intolerance, i.e. the opposite of cidal, e.g. [33] .
Several observations suggest that tolerance or phenotypic resistance is more important than stable azole resistance in the pathobiology of most Candida infections. Most clinical failures to FLZ occur with susceptible isolates. Stable azole resistance in non-OPC isolates is rare. For example, in one study, 40 of 40 breakthrough fungemias among neonates and infants were due to isolates that were susceptible to FLZ in vitro [187] . Among VVC patients, less than 4% of isolates were FLZ resistant, and in only one patient there was a documented transition to resistance during treatment. Indeed, FLZ susceptibility seemed irrelevant to RVVC patient outcome under FLZ therapy [188] . In our hands, most or all of these FLZ-resistant isolates are unstable and revert to susceptibility (unpublished observations), suggesting that their apparent resistance was phenotypic. Numerous small and large scale surveys of bloodstream isolates of C. albicans indicate that 97Á/100% are highly susceptible in vitro to FLZ and other azoles [189 Á/194] , despite breakthrough infections which occur at a rate of about 10% with high attributable mortality [195, 196] . Stable azole resistance is not a risk factor for patient outcome in non-OPC candidiasis patients [197] . The fungistatic response of C. albicans to FLZ, i.e. its tolerance of FLZ, is a critical factor here. Certainly, host factors such as prolonged neutropenia are crucial, but only because FLZ is only static, not cidal, in these patients. It needs underscoring, that C. albicans ' ability to tolerate exposure to FLZ, and probably to other forms of stress, is a prelude to phenotypic resistance, and is a precondition for mutation and resistance. On the latter point, FLZ exposure has been shown to increase mutagenic responses in C. albicans, such as chromosomal non-disjunctions, which in turn expose recessive alleles of as yet unknown genes that cause azole resistance [198] .
Another argument that tolerance to FLZ is important in clinical therapy is that, in the single infection site in which C. albicans is not tolerant, FLZ therapy is greatly enhanced. This optimal site for azole treatment is vaginal. Here, a single dose (150 mg) typically suffices to rapidly eradicate the infection [199] . In contrast, in oral mucosal infections, multiple doses are typically required of, for example, 14 daily doses of 100Á/400 mg [200] . The key difference is in the vaginal microenvironment, which contains about 20 mM acetic acid [201] . The combination of FLZ and 20 mM acetic acid is fungicidal [184] . It remains to be seen whether cases of recurrent VVC [202] occur in patients in which vaginal acetic acid is depleted.
Phenotypic resistance
In vitro, most isolates mount a reversible, adaptive response within a few hours in acidic media [184] and (unpublished results). On a longer time scale, and perhaps using a different mechanism, C. albicans can adapt to increasing concentrations of FLZ. In one study, the resistance was reversed by subculturing in the absence of FLZ, and no increase in MDR1 or CDR1 was detected [203] . Similar results are seen in some clinical FLZ-resistant isolates [204] . Studies of phenotypic resistance are largely ignored, probably since molecular analysis of stable mutations is more tractable.
What mechanisms might be responsible for adaptive responses to FLZ in C. albicans ? In one study, a series of C. albicans isolates from a BMT patient on FLZ showed the development of FLZ ''resistant'' isolates. These were shown to have elevated expression of CDR genes, but not ERG genes. No mutations occurred in ERG11 genes and sterol composition was not affected. In contrast to the stably resistant isolates recovered from OPC patients, these isolates gradually lost resistance upon subculture in non-selective media, concomitant with a decrease in expression of CDR genes. Conversely, subpopulations of initially susceptible isolates showed transient resistance upon exposure to FLZ, correlated with upregulation of transporters [205, 206] . An earlier study also induced FLZ resistant isolates by subculturing 12'/ days in 8'/ mg/ml FLZ, and the resistant phenotype was lost upon subculturing 14'/ days. In contrast to the study above, these isolates did not show elevated expression of CDR1, MDR1, or ERG11. Although no mention was made of CDR2, the possibility is that the phenotypic resistance mechanism of this isolate was different [207] . These two studies support the premise that phenotypic resistance is a regulatory response. Potentially, this involves upregulation of some of the same genes which, when mutated, confer resistance.
Is ''phenotypic switching'' in C. albicans responsible for some forms of phenotypic resistance? Most strains of C. albicans undergo high-frequency switching that alters their cellular and colony morphology [208] . There are indications that switching promotes survival under selective in vivo conditions [209, 210] . Switching is a regulatory process that involves transcriptional reprogramming by histone acetylases and deacetylases [211 Á/215] . Resistance to antifungals may also be affected by switching. Early studies linking resistance and switching were not impressive, and the demonstration that CDR3 is induced in opaque cells is uniterpretable in this context, since it has not yet been correlated with resistance [122] . However, Soll's group recently demonstrated that primary isolates from HIV patients undergo switching at a 100-fold elevated rate, and that, independent of antifungal therapy, specific morphologies have dramatically different susceptibilities to azoles and fluorocytosine. However, this was not true among the various subtypes deriving from laboratory strains that switch [216] . This is an exciting demonstration of the richer potential range of phenotypes of primary isolates and of in vivo pressures relative to laboratory strains and in vitro conditions. The authors cite as unpublished observations that some of the usual suspect genes are induced by switching; assuming that these data will be forthcoming, this suggests that resistance genes are just a subset of target genes whose regulation is altered by the switching regulator(s).
Phenotypic resistance is different than the ''trailing effect'' seen by select isolates in RPMI 1640 media under NCCLS conditions for MIC. The latter is seen only in a minority of isolates and occurs at pH !/6 [217, 218] ; adaptive growth is seen by most isolates, preferentially in acidic media (unpublished results and [184] ). Trailing strains are those which are inhibited for 24 hours under NCCLS conditions, but show slower growth at higher antifungal concentrations, blurring the assignment of a specific MIC, and often show fully confluent growth 24 hours later, even at high concentrations. One study showed that trailing strains show a higher than average number of polymorphisms in ERG11, but not generally higher levels of expression [219] . CDR1 was lower in the absence of FLZ, and inducible by FLZ to a greater extent, in trailing strains compared to susceptible but dose-dependent (SDD) strains. This study was limited by a lack of comparison to susceptible controls, and did not establish a clear mechanism by which trailing strains differ from susceptibles. Another study also showed that a trailing strain of C. albicans was inducible for ERG1, ERG11, CDR1, and CDR2, and that an inhibitor that interfered with these inductions blocked its trailing response to FLZ [90] . Again, this study does not address what key differences exist between trailing and non-trailing strains. Lower priorities have seemingly been applied to studies on trailing mechanisms, since these strains do not seem to pose a greater threat of resistance in systemic infections than susceptible strains [220] .
Tolerance pathways
These proposed inducible pathways for tolerance are not hypothetical. Two pathways to date are implicated in tolerance: cAMP-protein kinase A, and Ca-calmodulin-calcineurin pathways.
The calcineurin pathway in fungi is a stress response, signal transduction pathway recently recognized as essential for tolerance of C. albicans to FLZ (Fig. 3) . Calcineurin is a heterodimeric phosphatase; calciumdependent calmodulin binding is required for activation. In S. cerevisiae, Ca '' -bound calmodulin binds to calineurin, which can then remove an inhibiting phosphate on ScCzr1p, allowing it to enter the nucleus and activate transcription of stress response genes. The pathway is conserved in many fungi, although the phenotypic consequences of its inactivation varies with the species [221] . In C. albicans, calcineurin subunits are encoded by CNA1 and CNB1. While disruption of both alleles of CNA1 is not lethal, disruptants are killed when exposed to FLZ and other azoles, terbinafine, amorolfine, calcofluor white, Congo red, caffeine, SDS, brefeldin A, and mycophenolic acid. Disruptants that were more sensitive to Na ' , Li ' , and Ca '' , could not survive in serum, and were avirulent in a mouse infection model [33, 222] . Similar effects result from inhibition of calcineurin by cyclosporin A, which binds to cyclophilin, and the complex binds and inhibits calcineurin, or by FK506, which binds to FKBP12, preventing it from tethering calcineurin to its target proteins [32, 223, 224] . The fungicidal synergy of cyclosporin A and FLZ is not dependent on transporters CDR1, CDR2, MDR1, or FLU1, since the synergy is still evident in disruptants [225] . These are the only likely targets for these two agents, since the deletion of cyclophilin and FKBP12 results in lack of synergy of either inhibitor with FLZ. These observations indicate that the pathway is essential for responding to a variety of stress signals.
Consistent with findings in S. cerevisiae, disruption of CaCNA1 altered colony morphology. CaFKS1, a b-glucan synthase subunit, and CaPMC1, a calcium efflux protein, were upregulated by calcium or FLZ in a calcineurin-dependent manner, whereas CaCDR1, CaFKS3, CaPMR1, and CaPMR2 were not [33, 222] . Which gene, regulated by CNA1/CNB1, is required for tolerance to FLZ, is not known. Similar phenotypes were conferred by disruption of CNB1 [226] . These authors point out that inhibitors affecting wall structure, in contrast to those affecting membranes, are not synergistic with CsA. They show that a FLZ-resistant mutant with a mutation in ERG11 is susceptible to the FLZ-FK506 synergy, whereas FLZ-resistant mutants showing overexpression of CDR1 are not.
CaCZR1, based on its homology and ability to substitute for ScCZR1 in S. cerevisiae, was predicted to be the likely downstream target of calcineurin in C. albicans. However, its disruption did not reduce virulence in a disseminated mouse model, did not eliminate synergy between FK506 and fluconazole, did not confer hypersensitivity to salt stress, and changed susceptibility to fluconazole only modestly [227] . These observations show either that CaCRZ1 is not the primary target of calcineurin, or that there is a redundant gene.
Together, these papers show the paramount importance of the calcineurin pathway in conferring FLZ tolerance, and underscore that we do not know the critical genes that regulate or mediate the pathway to affect FLZ tolerance.
cAMP-Protein kinase A pathway
This pathway in S. cerevisiae is required for growth, carbohydrate synthesis, and recovery (release from G 0 ) after stress, and is an antagonist of the calcineurin stress response pathway [228] . This antagonism is mediated by phosphorylation of the nuclear localization signal of ScCrz1p, preventing its activation of calcineurin response genes [229] .
The cAMP-PKA pathway in C. albicans is likely required to facilitate the recovery process and resume growth after various stress conditions, perhaps an initial inhibition by FLZ. Crucial genes in this 2nd pathway essential for FLZ tolerance are CDC35, encoding the adenyl cyclase enzyme, and CAP, the cAMP-associated protein. Disruption of either gene results in hypersusceptibilty to azoles and terbinafine, as does incubation of wild type strains with adenyl cyclase inhibitor MDL-12330A. These hypersusceptibilities were overcome with exogenous cAMP. The FLZ-induced expression of CDR1 was blocked by the deletions or inhibitor [230] .
On this basis, we speculate that phenotypic resistance to FLZ may be a two step process: a tolerance response mediated by a calcineurin-induced mechanism, to allow survival, then resumption of growth from the inhibited state, mediated by cAMP-PKA activation of targets that remain to be identified. In this model, the apparent antagonism between the two pathways is actually a timing mechanism. Activated PKA phosphorylates the C. albicans equivalent of ScCrz1p, to shut down the calcineurin pathway once the stress response has achieved its goals.
Novel mechanisms for azole resistance
Other mechanisms of azole resistance exist, but space limitations preclude dealing with them in this review. To summarize, PDR16 and PDR17 control the phospholipid composition of the plasma membrane and may confer resistance when upregulated along with CDR1 [103, 231, 232] . ALK8 is a C. albicans homolog to alkane-inducible cytochrome P450 genes, whose overexpression confers resistance, possibly by modifiying the antifungal [233] . Potentially, FLZ resistance could be mediated by inhibiting uptake [234, 235] . Conversely, one study provides strong evidence that sequestration of FLZ into vesicular vacuoles is at least part of a resistance mechanism [236] .
Studies in S. cerevisiae and C. glabrata suggest that competent mitochondria are required for azole susceptibility [237 Á/247] . Furthermore, FLZ-resistant C. glabrata petites need not have irreversible mtDNA deletions. Petites that arose from insertion mutations in several nuclear genes needed for mitochondrial biogenesis were reversibly FLZ-resistant. The deficiency and the FLZ-resistance reverted at a very high rate, suggesting that an epigenetic mechanism was determining repiratory competence [248] .
Petites have induced levels of CDR1, suggesting that this is the means by which they are azole resistant. However, it is possible that there is more to mitochondrial-based resistance than CDR1 induction. It has been suggested that sterol depleted mitochondria spew out ROS that inhibit or kill the cell; dysfunctional mitochondria, incapable of generating ROS, are therefore benign, although there is some evidence to the contrary [249] . Another perplexing link between mitochondrial function and sterol metabolism is seen in ERG3 mutants in S. cerevisiae. Respiratory competent cells with ERG3 deletion are resistant to fluconazole, whereas petites with ERG3 deletions are not; petites are resistant only with a functional ERG3 gene [239] . The above studies argue that there is a complex link between mitochondrial function and antifungal susceptibilities. This has been difficult to study in C. albicans since the isolation of true petites is problematic and poorly documented.
Echinocandins
Echinocandins are natural lipopeptides, which now include synthetic derivatives, notably caspofungin (Merck; derived from pneumocandin B0 produced by Zalerion arboricola ), micafungin (Fujisawa; derived from Echinocandin B produced by Coleophoma empetri ), and anidulafungin (Vicuron; derived from Echinocandin B produced by Aspergillus nidulans ; Fig. 4 ) [250] . Each inhibits cell wall b-glucan synthesis by inhibiting b-glucan synthetase [251, 252] . They have broad-spectrum antifungicidal activities in vitro and in vivo (reviewed by [253, 254] ).
Echinocandins are also very promising in that resistant mutants are not cross-resistant to other classes of antifungals, and conversely, clinical isolates that are resistant to other antifungals, notably FLZ, are not typically cross-resistant to caspofungin [255 Á/257] . This stems from its inhibition of synthesis of a unique target, the essential (1 Á/3)b-D-glucans in the fungal cell wall. The primary targets in S. cerevisiae are b-glucan synthase subunits encoded by ScFKS1 or a paralogous gene encoded by ScFKS2. They are presumed to be alternate catalytic subunits; ScFKS2 expression is activated by calcineurin. Point mutations in either ScFKS gene confer resistance [258 Á/260] . In C. albicans, the same target enzyme is encoded by CaFKS1, with no paralog. Four of four independent spontaneous mutants, selected in vitro for resistance to semisynthetic echinocandin L-733,560, showed cross-resistance only to other echinocandins and had in vitro resistant b-glucan synthase activity [261] . Disruption of the resistant CaFKS1 allele in each mutant negated this resistance. This shows that mutation in either CaFKS1 allele is sufficient for resistance [262] . These Caspofungin resistant mutants were fully virulent in a mouse disseminated candidiasis model. Surprisingly, in this model, even resistant mutants were effectively treated with caspofungin [261] . However, transformants in which the susceptible allele had been disrupted, leaving only one resistant allele, were highly resistant in vivo [262] . Further analysis of point mutations in CaFKS1 that confer resistance will presumably be forthcoming from the Merck research team.
There are other mechanisms of resistance to echinocandins. Recently, CDR2 has been implicated as a resistance mechanism, since its overexpression in S. cerevisiae or Candida increases the MIC from 0.1 to 1.0 mg/ml [113] . While this increase is significant mechanistically, it should be emphasized that this level of resistance is 30-fold lower than that afforded by point mutations in FKS1 [261] . Other active efflux mechanisms seem incapable of conferring Caspofungin-resistance [263] . At least at low concentrations, both uptake and efflux of caspofungin by C. albicans appears to be mediated by a high-affinity facilitated transporter, not CDR2, that is energy independent [264] . Although mutants in this putative function have not yet reported, it is another potential resistance mechanism. Another resistance mechanism may underlie the ''paradoxical'' resistance to Caspofungin [265] . In this, 16% of clinical isolates of C. albicans are susceptible to Caspofungin at low concentrations, but resistant at higher concentrations. Over half of tested clinical isolates are killed at low concentrations but are tolerant at higher concentrations. These effects revert to wild type upon subculture. This effect was not seen for other echinocandins or in other species. The authors suggest that the higher concentrations induce or derepress a resistance mechanism, which has yet to be investigated. Global expression analysis of paradoxical strains, exposed to lower versus higher concentrations of Caspofungin, should be revealing. Taking a different approach, one group overexpressed S. cerevisiae cDNA clones in S. cerevisiae transformants and selected for caspofungin resistance. They isolated a single gene, SBE2, a golgi protein required for cell wall assembly, that conferred specific resistance when overexpressed, and hypersensitivity when deleted [266] . These early studies suggest that there are potentially many novel mechanisms for resistance to Caspofungin.
Genome-scaled functional analysis of caspofungin resistance in S. cerevisiae is a predictor of resistance mechanisms that may apply to C. albicans. A library of 4,787 individual knockout mutations were screened for resistance and hypersusceptibility. Twenty disruptants were hypersusceptible; eleven were involved in the PKC cell integrity pathway, and chitin, mannan, and ergosterol biosynthesis, including the target gene FKS1. Consistently, PKC inhibitor staurosporine was synergistic with caspofungin against A. fumigatus, A. nidulans, and A. flavus isolates that were resistant to caspofungin alone. Nine disruptants were resistant, and five of these encoded cell wall or signal transduction genes [267] .
Using the same approach, a different group identified an overlapping set of S. cerevisiae genes whose disruption altered susceptibility to Caspofungin [268] . Disruption of 53 genes resulted in hypersusceptibility, another 39 in resistance, using a less stringent definition of altered susceptibility than in the competing study. Notably, deletion of FKS2, but not FKS1, conferred resistance, as did CZR1, the calcineurindependent upstream activator of FKS2 [268] . One expects that FKS1 disruptants would be susceptible, since FKS2 is normally not expressed unless FKS1 is deleted, and since Fks2p is more sensitive to caspofungin than Fks1p. It is not clear why FKS2 disruptants would be resistant to Caspofungin. In the absence of additional information, it would seem that these strains would have the same susceptibility as wild type, since both express FKS1. From this open question, it seems that there is still much to be learned about the regulation of cell wall biosynthesis and its regulation.
From these two disruption studies in S. cerevisiae, it appears that agents that interfere with the PKC cell integrity pathway, and those conditions or mutations which inhibit compensatory changes in cell wall biosynthesis may act synergistically with caspofungin and allow effective treatment of strains and species that are relatively insensitive to caspofungin alone.
Preliminary data from our C. albicans overexpressant library indicate that overexpression of a gene with no known function or relationship to cell wall biogenesis confers resistance to Caspofungin.
5-Fluorocytosine
5-Fluorocytosine (FC) is a pyrimidine analogue that acts as a suicide inhibitor that must be salvaged by susceptible cells to be toxic. The pathway for FC, outlined in Fig. 5 , includes a cytosine-purine permease for uptake, a deaminase which is not present in humans, thereby explaining the basis for fungal specificity, and a uracil phosphoribosyltransferase, to generate the toxic intermediate F-UMP. This is incorporated into RNA via F-UTP, presumably inactivating its template function and also inhibiting RNA synthesis. It is also converted by ribonucleotide reductase to F-dUMP, which inhibits thymidylate synthase and DNA replication [269 Á/271] .
Resistance in clinical strains has long been recognized as a frequent occurrence, seen in up to 11 Á/15% of isolates, or more occasionally 35% of C. albicans isolates, depending on the site of the study and the patient types [272, 273] . This factor alone has limited the use of an otherwise potent fungicidal agent, which is now used mainly in combination with other antifungals or in cases that are refractory to azoles [274 Á/ 278] .
Recent molecular studies have all but confirmed the role of uracil phosphoribosyltransferase, formerly called UMP pyrophosphorylase, in resistance. Most clinical resistant isolates have a mutation in the FUR1 gene, formerly FCY1, encoding this enzyme. The mutation at C301T alters a conserved amino acid, is homozygous in FC-resistant strains, is heterozygous in strains with intermediate levels of resistance, and is confined to a single lineage, Clade I [279 Á/281]. The model is that a defective or deficient Fur1p cannot effectively convert FC to the toxic F-UMP, thereby providing resistance. We have confirmed this model by introducing wild type FUR1 into FC-resistant strains containing homozygous C310T mutations, and showing that the transformants were susceptible to FC (unpublished observations).
Evidence that mechanisms other than FUR1 inactivation are operative in C. albicans is suggested by early biochemical and genetic studies of C. albicans and C. glabrata . These studies point to deficiencies in cytosine permease, cytosine deaminase, or alterations in thymidylate synthase activities [269, 282, 283] . One of 25 clinical isolates showing FC resistance had a homozygous mutation in cytosine deaminase FCA1, although no evidence was presented that this was responsible for its resistance [281] . Our observation is that strains that are homozygous at FUR1 C310 still spontaneously mutate to FC resistance at a high frequency, suggesting that some other gene whose loss of activity confers resistance is non-allelic or heterozygous. We have identified a putative nucleotidase gene, termed here NUC1, by selecting for FC-resistance among a library of C. albicans transformants overexpressing wild type C. albicans genes, whose overexpression confers resistance to both FC and FOA. These transformants are not auxotrophic (unpublished observations). Presumably, this resistance results from depletion of the pool of toxic F-UMP (Fig. 5 ).
Other antifungals
Other antifungals have been analysed in enough detail to be intriguing, but space limitations prevent their discussion in this review. These include: rapamycin, a foot-in-the-door to the fascintating TOR pathway; aureobasidin A, an inhibitor of the sphingolipid biosynthesis pathway; deriviatives of natural peptides, e.g. histatins and lactoferrin; cyclic amino acid analogs PLD-118, formerly BAY10-8888 and cispentacin that seemingly target specific amino acyl tRNA synthetases; and sodarins, inhibitors of microbial but not human translation elongation factor 2 (eEF2). Future studies of these inhibitors and their target pathways are not only clinically important, but will tell new stories about fundamental mechanics of translation, cell death signaling, autophagy, and probably several other entities.
Future perspectives
The completion of the C. albicans genome sequence [112] has heralded in an exciting time for molecular geneticists in the field, and has allowed sudden leaps forward, for example in identifying TAC1 as a regulator of CDR1 and CDR2 [142] and in designing useful microarrays. This information and the vast reservoir of information from S. cerevisiae that it makes more accessible, will be the major contributor towards new understanding of C. albicans. Libraries of all-inclusive gene disruptants are not far off [3] . The function-based approach of gene overexpression is already facilitating discovery, particularly in those niches in which gene function is not readily apparent from sequence, notably in the identification of regulatory genes and in measuring effects of perturbing metabolic pathways that are targeted by antifungals. The efficient high copy shuttle vector [24] may also introduce other new tools, possibly gene inactivation by siRNA or antisense RNA. (While there are no clear homologs in yeasts for RISC or DICER proteins, nonhomologous pathways may conduct surveillance and destruction of yeast dsRNAs.) These tools, that have been underdeveloped in S. cerevisiae, would be very powerful additions in studying the diploid, largely asexual C. albicans.
More work is needed in characterizing clinical resistant strains, than the current focus on levels of expression of CDR1, CDR2, MDR1, and on ERG11 mutations. As additional genes are added to the list, hopefully RNA or cDNA from the initial studies will be available to widen the net. It seems likely that mutations that downregulate ERG3 or ERG25, or that upregulate ERG6 will be involved in resistance in clinical isolates. With a collection of genes which, when overexpressed confer AMB resistance, a better understanding of the interaction of the drug with fungal wall and membrane structures is likely. It would be an accomplishment to identify a target which when inhibited by a next-generation antifungal, would make AMB effective at much lower concentrations. Similarly, identification of critical target genes activated by calcineurin will facilitate our ability to make azoles fungicidal, and more generally, how to neutralize the abilty of our clever opponent, C. albicans, to bounce back from stresses of many sorts. Phenotypic resistance may be the sleeping giant in the field; understanding how important it is, and the mechanisms by which it is regulated and affected, may allow clinicians to get at that the still alarmingly high percentage of patients who do not respond to antifungals, despite harboring only in vitro susceptible strains. The detailed structurefunction analyses of the efflux pumps by many laboratories will facilitate the design of effective pump inhibitors, to make current antifungals more potent and cidal. In particular, a better understanding of the regulation of MDR1 is needed, since its upregulation by mutation seems to be the prevalent mechanism early in the development of resistance in clinical isolates.
Antifungals that hit targets outside the ergosterol pathway are important for the future of antifungal therapy, given the limitations of azoles as static agents with a restricted spectrum of susceptible species. Echinocandins are the major contributors for the present, but there is no room for complacency. As their use increases, we may stumble onto, or create, a lineage with intrinsic resistance or increased ability to mutate to resistance, as has been observed for FC. Understanding that most resistance in clinical isolates to FC is by blocked salvage, due to defective uridine phosphoribosyltransferase, closes the door on making structural modifications to FC to overcome resistance, unless nucleoside derivatives that can be imported but are still non-toxic can be found. More study of other antifungals is worth pursuing, even if they are not viable candidates for clinical use, because of what we know about the pathways they target and how perturbing those pathways affect other targets. Opportunity for inhibiting efflux pumps lies not only in designing agents that directly interact with the pumps, but also, for example, in perturbing the membrane environment in which they must function.
For any currently used antifungal, understanding the basis for resistance is paramount in designing modifications to current structures and blocking bypass mechanisms, in anticipation of the inevitable development of resistance in clinical isolates in current species, or in species now lurking in the shadows of low incidence and misidentification, waiting to emerge.
